Biomarkers have always been one of the hot topics in the field of drug research and development. Especially in the past decade, with the increasing attention to product innovation and research and development efficiency, the application of biomarkers has become more and more medicine. An indispensable part of the R&D strategy of enterprises and biotech companies.

Almost all biopharmaceutical products will cause a certain anti-drug antibody (ADA) response after entering the body, which refers to immune response. ADA may affect or change the pharmacodynamic effect between the therapeutic protein and its target. Its pharmacokinetic characteristics affect the efficacy of the drug, and in some cases may also cause serious adverse reactions and even endanger the life of the patient.

The concept of gene therapy was proposed in the early 1970s. The original concept was to introduce a normal copy of a gene to replace a mutated counterpart. Although there are now more alternatives, such as gene editing and base editing, it is still one of the main strategies that Accurant Biotech Inc., applies.